Skip to main content

Advertisement

Log in

How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?

  • Statin Drugs (MB Clearfield, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Statins are highly effective drugs prescribed to millions of people to lower LDL-cholesterol and decrease cardiovascular risk. The benefits of statin therapy seen in randomized clinical trials will only be replicated in real-life if patients adhere to the prescribed treatment regimen. But, about half of patients discontinue statin therapy within the first year, and adherence decreases with time. Patient, physician and healthcare system-related factors play a role in this problem. Recent studies have focused more on the patients’ perspectives on non-adherence. Adverse events are cited as the most common cause of statin discontinuation; thus, the healthcare provider must be willing to ally and dialogue with patients to address concerns and assess the risks and benefits of continued statin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.

    Article  PubMed  Google Scholar 

  2. Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553–5.

    Article  PubMed  CAS  Google Scholar 

  3. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.

    Article  PubMed  Google Scholar 

  4. •• Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. This large internet-based survey provides insights into the behavior and attitudes of current and former statin users. More effective dialogue between patients and healthcare providers may increase persistence of statin use, specially when the patient is concerned about adverse events.

    Article  PubMed  Google Scholar 

  5. Charland S, Agatep B, Epstein R, et al. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: results of the additional KIF6 risk offers better adherence to statins (AKROBATS) trial. JACC. 2012;59(13):E1848.

    Google Scholar 

  6. • Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3:CD004371. This review showed that the most promising intervention to increase adherence to lipid lowering drugs includes strategies to remind patients about their medications.

  7. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–16.

    Article  PubMed  Google Scholar 

  8. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87(9):1074–9.

    Article  PubMed  CAS  Google Scholar 

  9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–32.

    Article  PubMed  Google Scholar 

  10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.

    Google Scholar 

  11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383–1389.

  12. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008.

  13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.

    Article  PubMed  CAS  Google Scholar 

  14. • Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. This meta analysis showed that even in individuals considered to be at low risk for CV disease, LDL cholesterol reduction results in reduction in major vascular events. These individuals would not be treated under present guidelines.

    PubMed  CAS  Google Scholar 

  15. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

    Article  PubMed  CAS  Google Scholar 

  16. Superko HR, Roberts R, Agatston A, et al. Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises. Curr Atheroscler Rep. 2011;13(5):396–404.

    Article  PubMed  Google Scholar 

  17. Gotto Jr AM, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol. 2012;110(1 Suppl):3A–14.

    Article  PubMed  CAS  Google Scholar 

  18. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208–15.

    Article  PubMed  CAS  Google Scholar 

  19. Stagnitti M. Trends in Statins Utilization and Expenditures for the U.S. Civilian Noninstitutionalized Population, 2000 and 2005. Statistical Brief #205. In. Edited by Quality AfHRa, vol. 2011. Rockville, MD; 2008.

  20. (CDC) CfDCaP: Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol—United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep 2011;60(4):109–114.

    Google Scholar 

  21. Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999–2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcome. 2009;2(1):41–8.

    Article  Google Scholar 

  22. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5(5):338–67.

    Article  PubMed  Google Scholar 

  23. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198–208.

    Article  PubMed  Google Scholar 

  24. AIM-HIGH, Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011;161(3):471–477 e472.

    Google Scholar 

  25. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365(24):2250–1.

    Article  PubMed  CAS  Google Scholar 

  26. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i–33.

    Article  PubMed  Google Scholar 

  27. Scott R, Best J, Forder P, et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol. 2005;4:13.

    Article  PubMed  CAS  Google Scholar 

  28. Ebrahim S, Casas JP. Statins for all by the age of 50 years? Lancet. 2012;380(9841):545–7.

    Article  PubMed  Google Scholar 

  29. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA. 2009;302(19):2104–10.

    Article  PubMed  CAS  Google Scholar 

  30. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–21.

    Article  PubMed  Google Scholar 

  31. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.

    Article  PubMed  Google Scholar 

  32. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–3421.

    Google Scholar 

  33. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847–52.

    Article  PubMed  Google Scholar 

  34. Cutrona SL, Choudhry NK, Fischer MA, et al. Targeting cardiovascular medication adherence interventions. J Am Pharm Assoc (2003) 2012;52(3):381–397.

    Google Scholar 

  35. Calvert SB, Kramer JM, Anstrom KJ, et al. Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J 2012;163(4):657–665 e651.

    Google Scholar 

  36. Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des. 2011;17(33):3669–89.

    Article  PubMed  Google Scholar 

  37. Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459–66.

    PubMed  Google Scholar 

  38. • Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health. 2010;64(2):109–13. This is a simulation study showing that improving adherence to statin therapy rather than lowering the CV risk threshold for initiating statin therapy would prevent twice as many additional deaths.

    Article  PubMed  CAS  Google Scholar 

  39. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12.

    Article  PubMed  CAS  Google Scholar 

  40. Lamberts EJ, Nijpels G, Welschen LM, et al. Discontinuation of statins among patients with type 2 diabetes. Diabetes Metab Res Rev. 2012;28(3):241–5.

    Article  PubMed  CAS  Google Scholar 

  41. Bell KJ, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ. 2011;342:d12.

    Article  PubMed  Google Scholar 

  42. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.

    Article  PubMed  CAS  Google Scholar 

  43. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.

    Article  PubMed  Google Scholar 

  44. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.

    Article  PubMed  Google Scholar 

  45. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196–202.

    Article  PubMed  Google Scholar 

  46. Adams JR, Elwyn G, Legare F, Frosch DL. Communicating with physicians about medical decisions: a reluctance to disagree. Arch Intern Med. 2012;172(15):1184–6.

    PubMed  Google Scholar 

  47. Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005;2(5):e123.

    Article  PubMed  Google Scholar 

  48. Lattry P, Molimard M, Dedieu B: Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC 2011.

  49. Fung V, Sinclair F, Wang H, et al. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4–10.

    PubMed  Google Scholar 

  50. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800–11.

    Article  PubMed  CAS  Google Scholar 

  51. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373–418.

    Article  PubMed  CAS  Google Scholar 

  52. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.

    Article  PubMed  CAS  Google Scholar 

  53. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. In: FDA Drug Safety Communication. 2012.

  54. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. In: FDA Drug Safety Communication. 2011.

  55. • Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–71. Further analysis of the JUPITER study shows that new-onset diabetes develops in the group already at high risk of developing diabetes.

    Article  PubMed  CAS  Google Scholar 

  56. Standards of medical care in diabetes—2012. Diabetes Care 2012;35 Suppl 1:S11–63.

    Google Scholar 

  57. Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22.

    Article  PubMed  Google Scholar 

  58. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119(3):390–7.

    Article  PubMed  Google Scholar 

  59. Gossey JT, Whitney SN, Crouch MA, et al. Promoting knowledge of statins in patients with low health literacy using an audio booklet. Patient Prefer Adherence. 2011;5:397–403.

    PubMed  Google Scholar 

  60. Eussen SR, de Jong N, Rompelberg CJ, et al. Effects of the use of phytosterol/-stanol-enriched margarines on adherence to statin therapy. Pharmacoepidemiol Drug Saf. 2010;19(12):1225–32.

    Article  PubMed  CAS  Google Scholar 

  61. Eussen SR, Bouvy ML, Rompelberg CJ, et al. Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy. Pharmacoepidemiol Drug Saf. 2011;20(8):830–7.

    Article  PubMed  CAS  Google Scholar 

  62. Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008;51(4):435–43.

    Article  PubMed  CAS  Google Scholar 

  63. Shiffman D, Chasman DI, Zee RY, et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol. 2008;51(4):444–8.

    Article  PubMed  CAS  Google Scholar 

  64. Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008;51(4):449–55.

    Article  PubMed  CAS  Google Scholar 

  65. • Charland S, Agatep B, Schrader B, et al. Abstract 290: Statin Adherence in Males and Females, and the Impact of Knowledge of a Genetic Test: Results from the AKROBATS Trial. Circulation: Cardiovascular Quality and Outcomes 2012;5(Supplement 1). The utility of pharmacogenetic information to increase adherence was tested, and knowledge of kif6 carrier status increased adherence to statin therapy.

  66. •• Kalia N, Li D, Budoff M. Statin Therapy Adherence After Visualizing Coronary Calcium by Cardiac Computed Tomography. J Am Coll Cardiol. 2012;59(13s1):E1188. Increased adherence to statin therapy was achieved by having patients view their arteries lined with calcium on cardiac CT scan.

    Article  Google Scholar 

  67. • Nieuwkerk PT, Nierman MC, Vissers MN, et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. Am J Cardiol. 2012;110(5):666–72. Counseling patients on their CV risk factors improves adherence to statin therapy.

    Article  PubMed  Google Scholar 

  68. Liberman JN, Hutchins DS, Shrank WH, Slezak J, Brennan TA. Adherence to medication under mandatory and voluntary mail benefit designs. Am J Manag Care. 2011;17(7):e260–9.

    PubMed  Google Scholar 

  69. Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin. 2009;25(11):2765–75.

    PubMed  CAS  Google Scholar 

  70. Kamat SA, Bullano MF, Chang CL, Gandhi SK, Cziraky MJ. Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Curr Med Res Opin. 2011;27(5):961–8.

    Article  PubMed  CAS  Google Scholar 

  71. Gaw A, Tolmie E, Lindsay GM. The statin breakthrough—remembering to involve the patient. Cardiovasc Drugs Ther. 2004;18(5):343–4.

    Article  PubMed  Google Scholar 

  72. Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005;19(6):437–40.

    Article  PubMed  Google Scholar 

  73. Casebeer L, Huber C, Bennett N, et al. Improving the physician–patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009;10:48.

    Article  PubMed  Google Scholar 

  74. Lin GA, Trujillo L, Frosch DL. Consequences of not respecting patient preferences for cancer screening: opportunity lost. Arch Intern Med. 2012;172(5):393–4.

    Article  PubMed  Google Scholar 

  75. O'Malley PG. On motivating patients: a picture, even if worth a thousand words, is not enough. Arch Intern Med. 2012;172(4):309–10.

    Article  PubMed  Google Scholar 

  76. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30(8):669–75.

    Article  PubMed  Google Scholar 

  77. Golomb BA, Yang E, Denenberg J, Criqui MH. Statin-associated adverse effects. Circulation. 2003;107:e7028–9.

    Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jan L. Breslow.

Additional information

This article is part of the Topical Collection on Statin Drugs

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maningat, P., Gordon, B.R. & Breslow, J.L. How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?. Curr Atheroscler Rep 15, 291 (2013). https://doi.org/10.1007/s11883-012-0291-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-012-0291-7

Keywords

Navigation